Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
New CDC report backs COVID vaccine effectiveness in children as vaccine safety probe heats up at FDA
As regulatory uncertainty around COVID vaccines continues to swirl, a new report from the Centers for Disease Control and Prevention (CDC) showcases the benefits of the immunizations among children | ...
As it shifts strategic direction to prioritize its recently acquired ENvue feeding tube placement system, NanoVibronix is changing its name to reflect the new focus. | As it shifts strategic direction ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
European legislators have reached a deal on a major rewrite of the region's pharma policies, pushing forward a framework ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback